Secondary Prevention of Ischemic Stroke in Urban China

被引:85
|
作者
Wei, Jade W. [1 ]
Wang, Ji-Guang [2 ]
Huang, Yining [3 ]
Liu, Ming [4 ]
Wu, Yangfeng [5 ]
Wong, Lawrence K. S. [6 ]
Cheng, Yan [7 ]
Xu, En [8 ]
Yang, Qidong [9 ]
Arima, Hisatomi [1 ]
Heeley, Emma L. [1 ]
Anderson, Craig S. [1 ]
机构
[1] Royal Prince Alfred Hosp, George Inst Int Hlth, Camperdown, NSW 2050, Australia
[2] Shanghai Jiao Tong Univ, Ctr Epidemiol Studies & Clin Trials, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
[3] Peking Univ, Hosp 1, Dept Neurol, Beijing 100871, Peoples R China
[4] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China
[5] Peking Univ, Hlth Sci Ctr, George Inst China, Beijing 100871, Peoples R China
[6] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[7] Tianjin Med Univ, Gen Hosp, Tianjin, Peoples R China
[8] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Guangdong, Peoples R China
[9] Ctr S Univ, Xiangya Hosp, Changsha, Peoples R China
关键词
China; prevention; stroke; 1ST-EVER STROKE; ATTACK; INTERVENTION; GUIDELINES; ADHERENCE; VALIDITY; HISTORY; CARE;
D O I
10.1161/STROKEAHA.109.571463
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-We aimed to describe the uptake of proven secondary prevention strategies for ischemic stroke in urban China. Methods-In a prospective, multicenter, hospital-based registry of 4782 cases of acute ischemic stroke in China during 2006, the use of secondary prevention regimens was evaluated before hospital discharge and 3 and 12 months after stroke. Logistic regression analysis was performed to determine associations between various baseline variables and in-hospital use of antihypertensive, antiplatelet, and lipid-lowering therapies, and to identify variables associated with their continuation at 12 months. Results-In-hospital initiation of antihypertensive (63%), antiplatelet (81%), and lipid-lowering (31%) therapies was influenced favorably by previous use and comorbid cardiovascular risk factors and unfavorably by stroke severity. Antihypertensive use was well-maintained during follow-up, whereas use of antiplatelet and lipid-lowering therapy decreased (66% and 17%, respectively; P<0.001) by 12 months after stroke, with discontinuation related to patient and physician factors. Interpretation-There was a high level of uptake of secondary prevention for ischemic stroke in this nationwide sample of hospitalized patients in urban China. However, use of antiplatelet and lipid-lowering therapy declined substantially after discharge, apparently related to misperceptions of subsequent disease risk by both doctors and patients. (Stroke. 2010;41:967-974.)
引用
收藏
页码:967 / 974
页数:8
相关论文
共 50 条
  • [41] Secondary prevention of ischemic stroke: Challenging patient scenarios
    Lee, Klwon
    Brown, David M.
    Dressler, Daniel David
    Amin, Alpesh
    Jamieson, Dara G.
    Krakow, David
    Rahman, Saad
    Likosky, David J.
    JOURNAL OF HOSPITAL MEDICINE, 2008, 3 : S20 - S28
  • [42] Causes and Secondary Prevention of Acute Ischemic Stroke in Adults
    Jensen, Maerit
    Thomalla, Goetz
    HAMOSTASEOLOGIE, 2020, 40 (01): : 22 - 30
  • [43] Acute Secondary Prevention of Ischemic Stroke: Overlooked No Longer
    Bulwa, Zachary B.
    Mendelson, Scott J.
    Brorson, James R.
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [44] The utilization status of aspirin for the secondary prevention of ischemic stroke
    Ke Xian-jun
    Yu Yong-fei
    Guo Zhen-li
    Xu Kang
    Hai Hong
    Zhang Ai-he
    Jiang Hong
    Peng Hong
    CHINESE MEDICAL JOURNAL, 2009, 122 (02) : 165 - 168
  • [45] Combination antiplatelet agents for secondary prevention of ischemic stroke
    Griend, Joseph P. Vande
    Saseen, Joseph J.
    PHARMACOTHERAPY, 2008, 28 (10): : 1233 - 1242
  • [46] The cost burden for secondary prevention of ischemic stroke in Korea
    Kim, C. H.
    Rhee, H. Y.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S168 - S168
  • [47] Drug secondary prevention in postmenopausal women with ischemic stroke
    Goga, S.
    Zdrenghea, D.
    Sitar-Taut, A.
    Cebanu, M.
    Pop, D.
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2012, 11 : S83 - S84
  • [48] Statins and secondary prevention of ischemic and hemorrhagic stroke - Response
    Vergouwen, Mervyn D. I.
    de Haan, Rob J.
    Vermeulen, Marinus
    Roos, Yvo B. W. E. M.
    STROKE, 2008, 39 (07) : E114 - E114
  • [49] Recommendation on the treatment of hypertension in the secondary prevention of ischemic stroke
    Sierra, C.
    Castilla-Guerra, L.
    Masjuan, J.
    Gil-Nunez, A.
    Alvarez-Sabin, J.
    Egocheaga, M., I
    Armario, P.
    HIPERTENSION Y RIESGO VASCULAR, 2018, 35 (04): : E11 - E18
  • [50] Secondary prevention of ischemic stroke: overview of updated guidelines
    Mulic, Smaila
    Kahles, Timo
    Nedeltchev, Krassen
    THERAPEUTISCHE UMSCHAU, 2018, 75 (07) : 420 - 424